key: cord-0783572-rnbu9o4i
authors: Mathur, Natasha; Duffy, Robert F.; Chinn, Brandyn; McFarland, Miles M.; Gable, Brian P.; Clay, Christina M.; Heymann, Warren R.
title: Nonuremic calciphylaxis in a COVID‐19 patient
date: 2021-05-17
journal: Int J Dermatol
DOI: 10.1111/ijd.15661
sha: 552c9aae6929f8fd44338163b89a0f6e417d7235
doc_id: 783572
cord_uid: rnbu9o4i

nan

that has yet to be defined. The associations of calciphylaxis with thrombophilia and thrombosis are well known. 6,7 COVID-19 presumably served as a precipitant for her prior thromboembolism and calciphylaxis. Her workup to date has been unrevealing though.

Sodium thiosulfate remains the first-line treatment for uremic calciphylaxis. 3 Based on our patient's response to sodium thiosulfate, we recommend that its use be considered as firstline therapy for COVID-19 patients with calciphylaxis. 

Calciphylaxis: risk factors, diagnosis, and treatment

patients: a systematic review and meta-analysis

Concomitant calciphylaxis and COVID-19 associated thrombotic retiform purpura

Warfarin-induced calciphylaxis in a COVID-19 patient

Calciphylaxis: a disease of pannicular thrombosis

Histopathology of calciphylaxis: cohort study with clinical correlations

Funding source: None. doi: 10.1111/ijd.15661